Denali Advisors’s AstraZeneca AZN Stock Holding History

Denali Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Sell	7,025 -294	-4%	-$55.3K	0.13%	164
2026 Q1	$1.44M	Buy	7,319 +319	+5%	+$61.5K	0.16%	145
2025 Q4	$1.29M	Buy	7,000 +2,512	+56%	+$441K	0.14%	151
2025 Q3	$689K	Sell	4,488 -2,501	-36%	-$379K	0.08%	205
2025 Q2	$977K	Sell	6,989 -44	-0.6%	-$6.17K	0.1%	176
2025 Q1	$1.03M	Buy	7,033 +1,239	+21%	+$179K	0.12%	167
2024 Q4	$759K	Sell	5,794 -1,236	-18%	-$173K	0.08%	196
2024 Q3	$1.1M	Buy	+7,030	New	+$1.13M	0.12%	164

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Denali Advisors's AZN Position: Q2 2026 in Review

Denali Advisors reduced its AstraZeneca (AZN) stake by 4% in Q2 2026, selling an estimated $55.3K and leaving 7,025 shares worth $1.33M. The position accounts for 0.13% of the portfolio, ranked #164.

Denali Advisors first reported a position in AZN in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.44M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Denali Advisors held 7,025 shares of AstraZeneca worth $1.33M as of Q2 2026.
Denali Advisors sold 294 AstraZeneca shares in Q2 2026, an estimated $55.3K.
AstraZeneca made up 0.13% of Denali Advisors's portfolio in Q2 2026, its #164 holding.
Denali Advisors first reported a position in AstraZeneca in Q3 2024 and has held it in 8 quarters since.
Denali Advisors's AstraZeneca position peaked at $1.44M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.